US BROKER MOVES: SHEL upgraded at Morgan Stanley; PATH downgraded at Canaccord

Daily broker roundups of this kind rarely move the tape as a bundle; the names that travel are the ones where a rating change carries a thesis change rather than a target tweak. The standout here is the Vodafone double upgrade from Sell to Buy with a near-doubling of the target at a major house, a reversal pattern that has historically drawn more follow-through than single-notch moves because it forces fast-money positioning to cover rather than merely add. The Shell upgrade to Overweight sits within the recurring pattern of integrated oil re-ratings that cluster when houses turn on the sector's capital returns and upstream mix, and peer targets at the other majors are the usual tell for whether it is a single-analyst view or the start of a sector-wide revision cycle. The two-notch moves in small and mid caps, and the clustered downgrades in copper and protein names, tend to be stock-specific unless they spread to the peer set. On past form, initiations at biotechs with large implied upside move the underlying only where liquidity allows. The follow-on worth noting is whether any of these calls are echoed by rival desks in coming sessions, since corroboration, not the initial note, is what has historically sustained re-ratings.